Notice of Intent to Publish a Funding Opportunity Announcement for Diabetes Research Centers (P30 Clinical Trial Optional)

forecasted

The National Institute of Diabetes and Digestive and Kidney Diseases ( NIDDK ), intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for Diabetes Research Centers (DRCs). The DRCs are a key component of the overall NIH/NIDDK strategy to improve health of Americans with diabetes and related endocrine and metabolic disorders. The purpose of this Centers program is to create a community of preclinical and clinical diabetes researchers to enhance communication, multidisciplinary collaboration, mentoring and effectiveness of ongoing research in DRC topic areas. By providing an enrichment program, shared access to specialized technical resources (biomedical research cores) and a Pilot and Feasibility Program (P&F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that propose unique scientific themes or innovative resources are encouraged, especially in emerging scientific areas that have the potential to improve diabetes or metabolic health. Emphasis will be placed on Center programs that create a community of diabetes researchers, creates synergy with other NIH and NIDDK funded resources, and provides a rich mentoring environment for future diabetes researchers exploring innovative new ideas to prevent or cure diabetes and related metabolic disorders. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the P30 activity code. Investigators with expertise and insights into this area of Diabetes Research are encouraged to begin to consider applying for this new NOFO. In addition, collaborative investigations combining expertise in Immunology, Endocrinology, Metabolism, Endotyping or Artificial Intelligence will be encouraged, and these investigators should also begin considering applying for this application.